A Phase I/II Study Evaluating The Efficacy OF 5-Azacitidine And Bevacizumab In Advanced Renal Cell Carcinoma.

Trial Profile

A Phase I/II Study Evaluating The Efficacy OF 5-Azacitidine And Bevacizumab In Advanced Renal Cell Carcinoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Azacitidine (Primary) ; Bevacizumab (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2017 Status changed from active, no longer recruiting to discontinued.
    • 01 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2014 to 1 Jun 2015.
    • 28 Mar 2013 Planned End Date changed from 1 Mar 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top